Biological assays for interferons

被引:103
作者
Meager, A [1 ]
机构
[1] Natl Inst Biol Stand & Controls, Div Immunobiol, Potters Bar EN6 3QG, Herts, England
关键词
interferons; bioassays; potency measurements; standardisation;
D O I
10.1016/S0022-1759(01)00570-1
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Interferons (IFN) are potent biologically active proteins synthesised and secreted by somatic cells of all mammalian species. They have been well characterised, especially those of human origin, with respect to structure, biological activities, and clinical therapeutic effects. While structural differences are known to exist among the IFN species that constitute the "IFN family" and despite the existence of different receptors for type I and type II IFN, all species have been shown to exert a similar spectrum of in vitro biological activities in responsive cells. Principal among the biological activities induced by IFN is antiviral activity, the activity used to originally define IFN. Antiviral activity of IFN is mediated via cell receptors and is dependent on the activation of signalling pathways, the expression of specific gene products, and the development of antiviral mechanisms. Sensitivity of cells to IFN-mediated antiviral activity is variable, and depends on a number of factors including cell type, expression of IFN receptors and downstream effector response elements, effectiveness of antiviral mechanisms, and the type of virus used to infect cells. Nevertheless, by the judicious use of sensitive cell lines in combination with appropriate cytopathic viruses, effective assays to measure the antiviral activity have been developed. Historically, "antiviral assays" (AVA) were the first type of biological assays that were developed to measure the relative activity or potency of IFN preparations. However, the subsequent discoveries of several other biological activities of IFN has opened the way to the development of assays based on one or other of these activities. The latter include inhibition of cell proliferation, regulation of functional cellular activities, regulation of cellular differentiation and immunomodulation. More recently, the cloning of IFN responsive genes has led to the development of "reporter gene assays". In this case, the promoter region of IFN responsive genes is linked with a heterologous reporter gene, for example, Firefly luciferase or alkaline phosphatase, and transfected into an IFN-sensitive cell line. Stably transfected cell lines exposed to IFN increase expression of the reporter gene product in direct relation to the dose of IFN, the readout being a measure of this product's enzymic action. The current review aims to give a critical over-view of the development, specificity, standardisation and present use of the various biological assay methods now available for the quantification of IFN activity. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:21 / 36
页数:16
相关论文
共 101 条
[1]   SENSITIVITY OF EPSTEIN-BARR VIRUS TRANSFORMED HUMAN LYMPHOID-CELL LINES TO INTERFERON [J].
ADAMS, A ;
STRANDER, H ;
CANTELL, K .
JOURNAL OF GENERAL VIROLOGY, 1975, 28 (AUG) :207-217
[2]   MONOCLONAL-ANTIBODIES AND ENZYME IMMUNOASSAYS SPECIFIC FOR HUMAN INTERFERON (IFN)-OMEGA-1 - EVIDENCE THAT IFN-OMEGA-1 IS A COMPONENT OF HUMAN-LEUKOCYTE IFN [J].
ADOLF, GR .
VIROLOGY, 1990, 175 (02) :410-417
[3]   MOLECULAR-CLONING AND EXPRESSION OF THE HUMAN INTERFERON-GAMMA RECEPTOR [J].
AGUET, M ;
DEMBIC, Z ;
MERLIN, G .
CELL, 1988, 55 (02) :273-280
[4]   Nomenclature of the human interferon proteins [J].
Allen, G ;
Diaz, MO .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1996, 16 (02) :181-182
[5]  
Armstrong J A, 1981, Methods Enzymol, V78, P381
[6]   MOLECULAR MECHANISMS RESPONSIBLE FOR MALIGNANT TRANSFORMATION BY REGULATORY AND CATALYTIC DOMAIN VARIANTS OF THE INTERFERON-INDUCED ENZYME RNA-DEPENDENT PROTEIN-KINASE [J].
BARBER, GN ;
JAGUS, R ;
MEURS, EF ;
HOVANESSIAN, AG ;
KATZE, MG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (29) :17423-17428
[7]  
Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9
[8]  
BORDEN EC, 1982, CANCER RES, V42, P4948
[9]  
BOUILLON M, 1993, CANCER RES, V53, P826
[10]  
BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116